Array BioPharma (ARRY) PT Raised to $38 at Guggenheim; Sees as M&A Target
Tweet Send to a Friend
Guggenheim analyst Michael Schmidt raised the price target on Array BioPharma (NASDAQ: ARRY) to $38.00 (from $37.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
